MEENAKSHI HEGDE to Maximum Tolerated Dose
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Maximum Tolerated Dose.
Connection Strength
0.086
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 Sep 01; 5(9):1574-1583.
Score: 0.058
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.028